LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Corvus Pharmaceuticals Inc

Uždarymo kaina

3.94 0.77

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.89

Max

4.15

Pagrindiniai rodikliai

By Trading Economics

Pajamos

27M

15M

Pelnas, tenkantis vienai akcijai

-0.138

Darbuotojai

31

EBITDA

-1.8M

-9.9M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+232.48% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

34M

311M

Ankstesnė atidarymo kaina

3.17

Ankstesnė uždarymo kaina

3.94

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-06 14:31; UTC

Uždarbis

New York State Retirement Fund Posts 5.84% Annual Investment Return

2025-06-06 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 20:33; UTC

Uždarbis

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 19:36; UTC

Rinkos pokalbiai

Oil Futures Post Solid Weekly Gains -- Market Talk

2025-06-06 19:28; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

2025-06-06 18:46; UTC

Rinkos pokalbiai

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

2025-06-06 18:02; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Continues to Decline -- Market Talk

2025-06-06 16:35; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:34; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

2025-06-06 16:21; UTC

Rinkos pokalbiai

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-06 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-06 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-06 16:07; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-06-06 16:07; UTC

Rinkos pokalbiai

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

2025-06-06 15:53; UTC

Rinkos pokalbiai

Mexican Inflation Seen Rising in May -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

2025-06-06 15:36; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 15:33; UTC

Rinkos pokalbiai

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

2025-06-06 15:16; UTC

Rinkos pokalbiai

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

2025-06-06 15:05; UTC

Rinkos pokalbiai

Silver at its Highest In Nearly 15 Years -- Market Talk

2025-06-06 14:35; UTC

Rinkos pokalbiai

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-06-06 14:28; UTC

Rinkos pokalbiai

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

2025-06-06 14:15; UTC

Rinkos pokalbiai

Oil Rises on U.S.-China Talks Optimism -- Market Talk

2025-06-06 14:12; UTC

Uždarbis

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

2025-06-06 14:09; UTC

Uždarbis

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

232.48% į viršų

12 mėnesių prognozė

Vidutinis 13 USD  232.48%

Aukščiausias 17 USD

Žemiausias 11 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.